¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"receptor organ"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • solid organ
    °íÇüÀå±â, ½ÇÁú±â°ü
  • spiral organ
    ³ª¼±±â°ü
  • static organ
    ÆòÇü±â°ü
  • subcommissural organ
    ¸Â±³Â÷¹Ø±â°ü
  • subfornical organ
    ³úȰ¹Ø±â°ü
  • sucking organ
    ÈíÀαâ°ü
  • sense organ
    °¨°¢±â°ü
  • sensory organ
    °¨°¢±â°ü
  • smell organ
    Èİ¢±â°ü
  • taste organ
    ¹Ì°¢±â°ü
  • target organ
    Ç¥ÀûÀå±â
  • urinary organ
    ºñ´¢±â°ü, ¿ä·Î±â°ü
  • urogenital organ
    ºñ´¢»ý½Ä±â°ü
  • vestibular organ
    ¾È¶ã±â°ü, ÀüÁ¤±â°ü
  • vestibulocochlear organ
    ¾È¶ã´ÞÆØÀ̱â°ü, ÆòÇüû°¢±â°ü, ÀüÁ¤¿Í¿ì±â°ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • sensory organ
    °¨°¢±â°ü
  • smell organ
    Èİ¢±â°ü
  • solid organ
    ½ÇÁú±â°ü, ½ÇÁúÀå±â
  • spiral organ
    ³ª¼±±â°ü
  • static organ
    ÆòÇü±â°ü
  • subcommissural organ
    ¸Â±³Â÷¹Ø±â°ü
  • subfornical organ
    ³úȰ¹Ø±â°ü
  • sucking organ
    ÈíÂø±â°ü
  • target organ
    Ç¥ÀûÀå±â
  • taste organ
    ¹Ì°¢±â°ü
  • tribocytic organ
    ¼¼Æ÷À¶Çر¸
  • urinary organ
    ºñ´¢±â°ü
  • urogenital organ
    ºñ´¢»ý½Ä±â°ü
  • vestibular organ
    ¾È¶ã±â°ü, ÀüÁ¤±â°ü
  • vestibulocochlear organ
    ¾È¶ã´ÞÆØÀ̱â°ü, ÆòÇüû°¢±â°ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen receptor
    Ç׿ø¼ö¿ëü.
  • homing receptor
    ±Í¼Ò¼ö¿ëü
  • immunoglobulin receptor
    ¸é¿ª±Û·ÎºÒ¸° ¼ö¿ëü
  • insulin receptor
    Àν¶¸°¼ö¿ëü(áôé»ô÷).
  • insulin receptor
    Àν¶¸°¼ö¿ëü.
  • platelet receptor
    Ç÷¼ÒÆÇ¼ö¿ëü
  • postsynaptic receptor
    ¿¬Á¢Èļö¿ëü
  • prejunctional neuromuscular receptor
    ½Å°æ±ÙÁ¢ÇÕÀü¼ö¿ëü
  • pressor receptor
    ¾Ð·Â¼ö¿ëü(äâæ³áôé»ô÷).
  • pressor receptor reflex
    ¾Ð·Â¼ö¿ëü¹Ý»ç(äâæ³áôé»ô÷ÚãÞÒ).
  • pressure receptor
    ¾Ð¼ö¿ë±â, ¾Ð·Â¼ö¿ëü(¡­áôé»ô÷).
  • progesterone receptor
    ÇÁ·Î°Ô½ºÅ×·Ð(ÇÁ·ÎÁ¦½ºÅ×·Ð)¼ö¿ëü(¡­â¥é»ô÷)
  • receptor
    ¼ö¿ë±â
  • receptor amblyopia
    ¼ö¿ë±â¾à½Ã
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • early receptor potential
    Á¶±â½Ã¼¼Æ÷ÀüÀ§
  • electromagnetic receptor
    ÀüÀÚ±â(ï³í¸Ñ¨) ¼ö¿ëü(áôé»ô÷)
  • enzyme, receptor destroying (RDE)
    ¼ö¿ëüÆÄ±«È¿¼Ò
  • estrogen receptor protein
    ¸®¿¡½ºÆ®·Î°Õ ¼ö¿ë(áôé») ´Ü¹éÁú(Ó±ÛÜòõ).
  • estrogen receptor protein
    ¿¡½ºÆ®·Î°Õ¼ö¿ëü´Ü¹éÁú.
  • free receptor
    À¯¸®¼ö¿ëü(¡­áôé»ô÷).
  • homing receptor
    ±Í¼Ò¼ö¿ëü
  • hormone receptor
    È£¸£¸ó¼ö¿ëü.
  • immunoglobulin receptor
    ¸é¿ª±Û·ÎºÒ¸° ¼ö¿ëü
  • influenza virus receptor
    ÀÎÇ÷翣ÀÚ¹ÙÀÌ·¯½º ¼ö¿ëü
  • insulin receptor
    Àν¶¸°¼ö¿ëü.
  • insulin receptor
    Àν¶¸°¼ö¿ëü(áôé»ô÷).
  • interferon (INF) receptor
    ÀÎÅÍÆä·Ð ¼ö¿ëü
  • kapa receptor
    Ä«ÆÄ ¼ö¿ëü
  • labyrinthine receptor
    ¹Ì·Î¼ö¿ë±â
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
OAR organ at risk
OBF organ blood flow
OC obstetrical conjugate; occlusocervical; office call; on call; only child; optic chiasma; oral contra...
OPO Organ Procurement Organization
OS left eye [Lat. oculus sinister]; occipitosacral; occupational safety; office surgery; Omenn syndrome...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
OAR Organ at Risk
OC Organ culture
SOFA Sequential Organ Failure Assessment
SEOPF South Eastern Organ Procurement Foundation
SCO Subcommissural organ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • critical organ
    Ç¥Àû Àå±â, À§ÇØ Àå±â, ÇѰè Àå±â
  • dental organ
    Ä¡¾Æ±â
    Ä¡¾Æ Çü¼º °úÁ¤¿¡¼­ ¹ý¶ûÁúÀ» Çü¼ºÇÏ°Ô µÉ ºÎºÐ.
  • digestive organ
    ¼ÒÈ­ ±â°ü
    µ¿¹°ÀÌ ¼·ÃëÇÑ ¿µ¾ç¼Ò¸¦ ÀúÀå, ¼ÒÈ­, Èí¼öÇÏ´Â ÀÛ¿ëÀ» °¡Áø ±â°ü. ¼ÒÈ­±â¶ó°íµµ ÇÑ´Ù. ¿ø»ýµ¿¹° Áß¿¡¼­µµ ¤½Å¹ú·¹´Â ¸öÀÇ ÀϺο¡ ¸ÔÀ̸¦ ¼·ÃëÇÏ´Â ÀÔ°ú ½Äµµ¿Í °°Àº ¼¼Æ÷ ±â°üÀ» º¼ ¼ö ÀÖÀ¸³ª, º»·¡ÀÇ ¼ÒÈ­ ±â°üÀº ÇØ¸éµ¿¹° À̻󿡼­ ¹ß´ÞµÇ¾î ÀÖ´Ù. ôÃß µ¿¹°ÀÇ ¼ÒÈ­±â°üÀÌ °¡Àå ¹ß´ÞÇÏ¿© ±¸°­, ÀÌ, Çô, ÀεÎ, ½Äµµ, À§, Àå
  • douching : a jet or current of water, sometimes a dissolved medicating or cleansing agent, applied to a body part, organ or cavity for medicinal or hygienic purposes.

    dough

    ¹ÝÁ×ÇÑ °Í, ³¯ ºÐ
  • embryonic organ
    ¹è¾Æ ±â°ü
  • enamel organ
    ¹ý¶û±â
  • end-organ
    Á¾¸» ±â°ü, ¸»´Ü±â, Á¾¸» ½Å°æ ¼Òü
    Áö°¢ ½Å°æÀÇ ÇÇÆ÷µÈ Ä¿´Ù¶õ Á¾¸»ºÎ.
  • endocrine organ
    ³»ºÐºñ ±â°ü
    ³»ºÐºñ ±â´ÉÀ» ´ã´çÇÏ´Â ½Åü ±â°üÀ¸·Î ³úÇϼöü, ½Ã»ó ÇϺÎ, °©»ó¼±, ÃéÀå, ºÎ½Å, ºÎ°©»ó¼±°ú »ý½Ä ±â°üÀÌ ÀÖ´Ù.
  • epithelial enamel organ
    »óÇǼº ¹ý¶û±â
  • excretory organ
    ¹è¼³ ±â°ü
  • hearing organ
    û°¢ ±â°ü
    À½À» ´À³¢´Âµ¥ »ç¿ëµÇ´Â ±â°üÀ¸·Î external acoustic meatus¸¦ ºñ·ÔÇÏ¿© ear drum µîÀ» Æ÷ÇÔÇÑ´Ù.
  • homologous organ
    »óµ¿ ±â°ü
  • male genital organ
    ³²ÀÚÀÇ »ý½Ä±â, ³²¼º ¼º±â
  • male organ
    ³²¼º ±â°ü, ¼ö±â°ü, ¿õ¼º±â
  • mandibular affected organ
    ±â°ü¿¡ ¿µÇâÀ» ÁÖ´Â ÇϾÇ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
enamel organ Epithelial cells surrounding the dental papilla and differentiated into three layers: the inner enamel epithelium, consisting of ameloblasts which eventually form the enamel, and the enamel pulp and external enamel epithelium, both of which atrophy and disappear before and upon eruption of the tooth, respectively.
(12 Dec 1998)
end organ The special structure containing the terminal of a nerve fibre in peripheral tissue such as muscle, tissue, skin, mucous membrane, or glands.
See: ending.
(05 Mar 2000)
Jacobson's organ A specialised part of the olfactory system located anteriorly in the nasal cavity within the nasal septum. Chemosensitive cells of the vomeronasal organ project via the vomeronasal nerve to the accessory olfactory bulb. The primary function of this organ appears to be in sensing pheromones which regulate reproductive and other social behaviours. While the structure has been thought absent in higher primate adults, data now suggests it may be present in adult humans.
(12 Dec 1998)
floating organ An organ with loose attachments, permitting its displacement.
Synonym: floating organ, ptotic organ.
(05 Mar 2000)
flower-spray organ of Ruffini One of the two types of sensory nerve ending associated with the neuromuscular spindle (the other being the annulospiral ending); in this type, the fibre branches spread out upon the surface of the intrafusal fibres like a spray of flowers.
Synonym: flower-spray organ of Ruffini.
(05 Mar 2000)
foetal organ maturity <embryology> Functional competence of specific foetal organs or body systems.
In humans, it is usually assessed by analysis of amniotic fluid, as in the assessment of foetal lung maturity by analysis for components of pulmonary surfactant.
(08 Mar 2000)
lateral line sense organ A structure in fish consisting of a long groove or canal extending along each side of the trunk and tail and branching in the head region; the groove or tube is lined with neuroepithelial cells, some of which are in groups known as neuromasts; its function appears to be the detection of vibrations of low frequency.
Synonym: neuromast organ.
(05 Mar 2000)
acetylcholine receptor antibodies <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream.
Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission.
Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy.
AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis.
AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis.
Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis.
Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued.
Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears.
(29 Dec 1997)
amino acid receptor <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor.
(18 Nov 1997)
AMPA receptor <cell biology> Glutamate operated ion channel.
See: excitatory amino acid receptor channels.
(05 Feb 1998)
ANP receptor <molecular biology> Family of 3 receptors for atrial natriuretic peptide. ANP A and ANP B have intracellular guanylate cyclase and protein kinase like domains. ANP C, shares the extracellular ligand binding and transmembrane domains, but lacks the functional intracellular domains and is not thought to be involved in signal transduction.
(18 Nov 1997)
asialoglycoprotein receptor A surface receptor found in hepatocytes that binds galactose-terminal glycoproteins; thus, this receptor removes those proteins from circulation and they are in turn acted upon by hepatocyte lysosomes.
(05 Mar 2000)
auditory receptor cells Columnar cell's in the epithelium of the organ of Corti, having hairs (stereocilia) on their apical ends.
See: Corti's cells.
(05 Mar 2000)
beta-adrenergic receptor blocking agent A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable.
Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker.
(05 Mar 2000)
beta-adrenergic receptor kinase <enzyme> Cyclic-AMP protein kinase which specifically phosphorylates the agonist-occupied form of beta-adrenergic receptor
Registry number: EC 2.7.1.-
Synonym: beta-ar kinase, beta-adrenergic receptor kinase 1, g-protein-coupled receptor kinase 2, grk2 (kinase), beta-adrenergic receptor kinase 2, beta-ar kinase 2
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á